Status:
COMPLETED
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
Lead Sponsor:
GlaxoSmithKline
Conditions:
Nausea and Vomiting, Postoperative
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- History of PONV and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain types of abdominal, breast or shoulder surgeries.
- Exclusion criteria:
- Pregnant or breastfeeding.
- Taking certain medications.
- Have certain pre-existing medical conditions.
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
482 Patients enrolled
Trial Details
Trial ID
NCT00326248
Start Date
March 1 2006
End Date
July 1 2006
Last Update
October 26 2016
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Montgomery, Alabama, United States, 36106
2
GSK Investigational Site
Sheffield, Alabama, United States, 35660
3
GSK Investigational Site
Phoenix, Arizona, United States, 85032
4
GSK Investigational Site
Los Angeles, California, United States, 90033